Exagen (XGN) Stock Price, News & Analysis

Company Overview

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel. These tests combine proprietary immunoassay technology with algorithm-driven analysis to deliver more precise and actionable diagnostic insights. All assays are performed in Exagen’s CLIA-certified, CAP-accredited laboratory to ensure consistent quality and reliability.

Exagen works closely with rheumatologists, immunologists and other healthcare providers across the United States, and is pursuing strategic partnerships to extend its reach into European markets. By filling critical gaps in standard autoimmune testing, the company aims to support earlier diagnosis, guide treatment decisions and improve long-term patient outcomes.

The company is led by President and Chief Executive Officer Stephen Heyser, whose background spans diagnostics, biotech and laboratory services. Under his leadership, Exagen continues to invest in research and development to enhance its existing testing platform and explore new assay applications within the autoimmune space.

Key Stats

• Today's Range: $9.75 to $9.89
• 50-Day Range: $6.74 to $10.10
• 52-Week Range: $2.38 to $10.34
• Volume: 61,101 shs
• Average Volume: 227,469 shs
• Market Capitalization: $217.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.25
• Consensus Rating: Buy

Exagen Stock Analysis - MarketRank™

Exagen scored higher than 90% of companies evaluated by MarketBeat, and ranked 110th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Exagen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Exagen has a consensus price target of $11.25, representing about 14.5% upside from its current price of $9.83.

Amount of Analyst Coverage

Exagen has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Exagen are expected to grow in the coming year, from ($0.88) to ($0.57) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Exagen is -11.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Exagen is -11.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Exagen has a P/B Ratio of 18.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.75% of the float of Exagen has been sold short.

Short Interest Ratio / Days to Cover

Exagen has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exagen has recently decreased by 60.88%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Exagen does not currently pay a dividend.

Dividend Growth

Exagen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.29

Percentage of Shares Shorted

3.75% of the float of Exagen has been sold short.

Short Interest Ratio / Days to Cover

Exagen has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exagen has recently decreased by 60.88%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Exagen has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Exagen this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Exagen to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Exagen insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.60% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XGN Stock Analysis - Frequently Asked Questions

How have XGN shares performed this year?

Exagen's stock was trading at $4.10 at the start of the year. Since then, XGN stock has increased by 139.7% and is now trading at $9.8260.

How were Exagen's earnings last quarter?

Exagen Inc. (NASDAQ:XGN) posted its quarterly earnings results on Tuesday, July, 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.18). The business earned $17.20 million during the quarter, compared to the consensus estimate of $16.25 million. Exagen had a negative trailing twelve-month return on equity of 130.38% and a negative net margin of 28.85%.
Read the conference call transcript.

When did Exagen IPO?

Exagen (XGN) raised $50 million in an initial public offering on Thursday, September 19th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO.

Who are Exagen's major shareholders?

Exagen's top institutional investors include Balyasny Asset Management L.P. (3.27%), Kennedy Capital Management LLC (1.41%), Russell Investments Group Ltd. (1.00%) and FourWorld Capital Management LLC (0.95%). Insiders that own company stock include Nmsic Co-Investment Fund, LP, James L L Tullis, John Aballi, Kamal Adawi and Mark Hazeltine.
View institutional ownership trends.

How do I buy shares of Exagen?

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Exagen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Exagen investors own include Chemours (CC), Ovintiv (OVV), Himax Technologies (HIMX), ImmunoGen (IMGN), Cassava Sciences (SAVA), CNX Resources (CNX) and Ford Motor (F).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 9/09/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:XGN
• CIK: 1274737
• Web: www.exagen.com
• Phone: 760-560-1501
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Exagen: $11.25
• High Price Target: $12.00
• Low Price Target: $10.00
• Potential Upside/Downside: +14.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.11 million
• Net Margins: -28.85%
• Pretax Margin: -28.76%
• Return on Equity: -130.38%
• Return on Assets: -34.69%

Debt

• Debt-to-Equity Ratio: 1.06
• Current Ratio: 4.95
• Quick Ratio: 4.95

Sales & Book Value

• Annual Sales: $55.64 million
• Price / Sales: 3.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.54 per share
• Price / Book: 18.22

Miscellaneous

• Outstanding Shares: 22,000,000
• Free Float: 19,231,000
• Market Cap: $216.48 million
• Optionable: Optionable
• Beta: 1.60